KL-A167
Regimen
- Experimental
- KL-A167 (anti-PD-L1 antibody, Sichuan Kelun-Biotech) 900 mg IV every 2 weeks until confirmed progression
- Control
- none
Population
Previously treated recurrent or metastatic NPC; platinum-pretreated; enrolled at multiple Chinese centers; evaluated for EBV DNA biomarker correlation
Key finding
KL-A167 (Kelun-Biotech domestic Chinese anti-PD-L1 antibody) demonstrated a 26.5% ORR in platinum-pretreated RM NPC, with durable responses (median DOR 12.4 months). Baseline low EBV DNA was consistently associated with better efficacy across DCR, PFS, and OS endpoints. No treatment-related deaths occurred. These results are similar to POLARIS-02 (toripalimab, 20.5% ORR), suggesting a class effect for ICI monotherapy in 2L NPC.
Source: PMID 36879786